Duchesnay

Focus: Duchesnay is a women's health-focused biotechnology company based in Blainville, Quebec, specializing in small molecules and devices for vaginal atrophy and pregnancy-related conditions.

Women's Health

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Duchesnay

AI assessmentNot Hiring

No open roles listed right now. Follow Duchesnay to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

1 in 5yr

OSPHENA

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

OSPHENA

Vaginal atrophy, vaginal dryness

$5M Part D

LOE Approaching

Help build intelligence for Duchesnay

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused women's health niche with meaningful unmet medical needs in vaginal atrophy and pregnancy complications.
Established revenue base from OSPHENA generating $5M in Part D spending provides near-term stability.
Smaller scale environment may offer faster decision-making and visible individual impact compared to Big Pharma.

Watch Out For

Severe revenue concentration risk: 99% dependent on OSPHENA, which faces patent cliff in July 2028 with only $5M at stake.
Minimal pipeline depth with only 3 Phase 3 programs and no early-stage innovation evident; limited career growth trajectory.
Only 1 active job opening signals minimal hiring and organizational stagnation despite biotechnology classification.

Generated by Claude from Duchesnay's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Flagship product representing 99% of company revenue; patent protection expires July 2028, creating existential revenue cliff.

DICLEGIS

Nausea and vomiting of pregnancy

$17K Part D

Peak

Established pregnancy indication with no exclusivity cliff; generates minimal revenue compared to OSPHENA.

BONJESTA

Nausea and vomiting of pregnancy

$39K Part D

Peak6.7yr

Extended-release formulation of doxylamine/pyridoxine with longer exclusivity runway; modest revenue contribution.